Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
The incidence of type 2 diabetes in developed countries is increasing yearly with a significant negative impact on patient quality of life and an enormous burden on the healthcare system. Current biguanide and thiazolidinedione treatments for type 2 diabetes have a number of clinical limitations, the most serious long‐term limitation being the eventual need for insulin replacement therapy (Table 1). Since 2007, drugs targeting the glucagon‐like peptide‐1 (GLP‐1) receptor have been marketed for the treatment of type 2 diabetes. These drugs have enjoyed a great deal of success even though our underlying understanding of the mechanisms for their pleiotropic effects remain poorly characterized even while major pharmaceutical companies actively pursue small molecule alternatives. Coupling of the GLP‐1 receptor to more than one signalling pathway (pleiotropic signalling) can result in ligand‐dependent signalling bias and for a peptide receptor such as the GLP‐1 receptor this can be exaggerated with the use of small molecule agonists. Better consideration of receptor signalling pleiotropy will be necessary for future drug development. This is particularly important given the recent failure of taspoglutide, the report of increased risk of pancreatitis associated with GLP‐1 mimetics and the observed clinical differences between liraglutide, exenatide and the newly developed long‐acting exenatide long acting release, albiglutide and dulaglutide. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue‐5
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 4×
“In contrast, similar weight loss is observed in T2DM patients receiving both long- and short-acting GLP-1 mimetics (Drucker et al., 2008; Buse et al., 2009), consistent with the gastric motility independent decrease in food intake seen in ICV-treated rats (Turton et al.”
BackgroundResultInfluentialGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 2×
“In both animals and humans, GLP-1 enhances satiety (Tang-Christensen et al., 1996; Turton et al., 1996; Flint et al., 1998; Näslund et al., 1998; Williams et al., 2009; Kanoski et al., 2011; Renner et al., 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998;…”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 3×
“, 2000; 2002) and some showing enhanced sensitivity (Egan et al., 2002; Zander et al., 2002; Meneilly et al., 2003).”
BackgroundMENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“GLP-1 is rapidly cleaved between positions 8 and 9 by the widely expressed serine protease DPPIV into GLP-1(9-36)amide (and GLP-1(9-37)) giving a circulation half life of 2–3 min (Mentlein et al., 1993b; Deacon et al., 1995; Kieffer et al., 1995; Hansen et al., 1999).”
BackgroundDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“In contrast, similar weight loss is observed in T2DM patients receiving both long- and short-acting GLP-1 mimetics (Drucker et al., 2008; Buse et al., 2009), consistent with the gastric motility independent decrease in food intake seen in ICV-treated rats (Turton et al.”
ResultBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 2×
“…Journal of Pharmacology (2014) 171 1114–1128 1115 been shown to have cardioprotective and glucoregulatory actions when pharmacologically dosed (Nikolaidis et al., 2005; Meier et al., 2006; Elahi et al., 2008) and, in model animals, may exert effects independent of GLP-1R (Ban et al., 2008; 2010).”
BackgroundDrucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“GLP-1, acting via the GLP-1R, causes acute potentiation of GSIS, regulated primarily by signalling through the stimulatory Gα (Gαs) subunit to activate adenylate cyclase and increase intracellular cAMP (Drucker et al., 1987; Holst et al., 1987; Mojsov et al., 1987).”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Plasma Insulin Response to Oral and Intravenous Glucose Administration1
ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · cited 2×
“The observation that oral glucose administration results in significantly higher pancreatic insulin secretion compared with intravenous dosing to the same plasma concentration gave rise to the idea of an entero-insular axis that was responsible for this enhancement (Elrick et al., 1964; Mcintyre et al., 1964).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 2×
“The insulinotropic action of GLP-1 appears to be entirely mediated by the GLP-1 receptor (GLP-1R) (Scrocchi et al., 1996) [we note that the official NC-IUPHAR nomenclature (Alexander et al., 2013) for this receptor is GLP-1 and have used GLP-1R to aid distinction between ligand and receptor].”
BackgroundDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792 · cited 1×
“GLP-1 is rapidly cleaved between positions 8 and 9 by the widely expressed serine protease DPPIV into GLP-1(9-36)amide (and GLP-1(9-37)) giving a circulation half life of 2–3 min (Mentlein et al., 1993b; Deacon et al., 1995; Kieffer et al., 1995; Hansen et al., 1999).”
BackgroundNew Interpretation of Oral Glucose Tolerance
Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · cited 2×
“The observation that oral glucose administration results in significantly higher pancreatic insulin secretion compared with intravenous dosing to the same plasma concentration gave rise to the idea of an entero-insular axis that was responsible for this enhancement (Elrick et al., 1964; Mcintyre et al., 1964).”
BackgroundCreutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 2×
“Isolated human islets are also protected from apoptosis by GLP-1 (Farilla et al., 2003); however, this may be compensatory due to loss of tonic stimulation of cAMP (compare Xie et al.”
BackgroundLarsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654 · cited 6×
“Biology of GLP-1 synthesis, secretion and metabolism Tissue-specific post-translational cleavage of proglucagon generates glucagon in pancreatic α-cells (Patzelt et al., 1979) and GLP-1, GLP-2, oxyntomodulin and glicentin in intestinal L-cells (Orskov et al., 1987; Eissele et al., 1992) and the brain (Drucker and Asa,…”
BackgroundInfluentialHerrmann, C., Göke, R., Richter, G., Fehmann, H.-C., Arnold, R., & Göke, B. (2009) · Digestion · doi:10.1159/000201231 · Cited by 597
Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats
Tang-Christensen, M., Larsen, P. J., Goke, R., Fink-Jensen, A., Jessop, D. S., Moller, M., & Sheikh, S. P. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r848 · Cited by 597
Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats
Farilla, L., Hui, H., Bertolotto, C., Kang, E., Bulotta, A., Di Mario, U., & Perfetti, R. (2002) · Endocrinology · doi:10.1210/en.2002-220405 · Cited by 502 · cited 2×
“Activation of the GLP-1R on pancreatic β-islets results in potentiation of glucose-dependent insulin secretion as well as improvements in beta cell function and mass in animal models (Xu et al., 1999; Perfetti et al., 2000; Stoffers et al., 2000; Tourrel et al., 2001; Farilla et al., 2002; Rolin et al., 2002; Wang and…”
BackgroundcAMP-GEFII is a direct target of cAMP in regulated exocytosis
Ozaki, N., Shibasaki, T., Kashima, Y., Miki, T., Takahashi, K., Ueno, H., Sunaga, Y., Yano, H., Matsuura, Y., Iwanaga, T., et al. (2000) · Nature Cell Biology · doi:10.1038/35041046 · Cited by 481 · cited 7×
“This occurs via two intermediates, protein kinase A (PKA) and the guanine nucleotide exchange factor Epac2 (Ozaki et al., 2000; Kang et al., 2001; Eliasson et al., 2003).”
BackgroundInfluentialGLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 3×
“Beyond the above tissues, which are obvious physiological targets for GLP-1, GLP-1R expression has been reported on kidney (Korner et al., 2007; Schlatter et al., 2007) and lung (Kanse et al., 1988; Richter et al., 1990; 1993; Korner et al., 2007), although expression in the human lung is…”
BackgroundResultGöke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 2×
“…system mRNA for the GLP-1R can be detected in the thalamus, hypothalamus and brainstem in both rodents (Shughrue et al., 1996; Merchenthaler et al., 1999; Yamamoto et al., 2003) and humans (Alvarez et al., 2005) and is consistent with rodent in situ radioligand binding data (Göke et al., 1995).”
ResultSingh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467 · cited 1×
“While there is no mechanistic data to explain these exocrine pancreatic effects, recent meta analysis on the incidence of pancreatitis in T2DM patients shows a doubling in relative risk for those using GLP-1 therapies (Singh et al., 2013).”
BackgroundGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432 · cited 2×
“, 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998; Delgado-Aros et al., 2002; Schirra et al., 2002; 2006; Nagell et al., 2006; Hayes et al., 2008; Hellström et al., 2008).”
BackgroundYamamoto, H., Lee, C. E., Marcus, J. N., Williams, T. D., Overton, J. M., Lopez, M. E., Hollenberg, A. N., Baggio, L., Saper, C. B., Drucker, D. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215595 · Cited by 429
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427 · cited 2×
“…slowing in gastric emptying (Meier et al., 2005; Linnebjerg et al., 2008); however, this effect is subject to tachyphylaxis (Nauck et al., 2011) and as a result, long-acting GLP-1 ana- logues are less efficacious in controlling postprandial glucose excursion (Degn et al., 2004; Buse et al., 2009).”
BackgroundNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 2×
“, 2008); however, this effect is subject to tachyphylaxis (Nauck et al., 2011) and as a result, long-acting GLP-1 analogues are less efficacious in controlling postprandial glucose excursion (Degn et al.”
BackgroundKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 2×
“…humans, GLP-1 enhances satiety (Tang-Christensen et al., 1996; Turton et al., 1996; Flint et al., 1998; Näslund et al., 1998; Williams et al., 2009; Kanoski et al., 2011; Renner et al., 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998; Delgado-Aros et al., 2002;…”
BackgroundPanjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · cited 2×
“, 2007) use immunocytochemistry to demonstrate GLP-1R expression in hepatic portal vein nerve terminals; however, it must be noted that the antibody used is no longer available from AbCam, and the replacement does not recognize the GLP-1R (Panjwani et al., 2013).”
BackgroundKorner, J., Bessler, M., Inabnet, W., Taveras, C., & Holst, J. J. (2007) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2007.08.004 · Cited by 344 · cited 6×
“…physiological targets for GLP-1, GLP-1R expression has been reported on kidney (Korner et al., 2007; Schlatter et al., 2007) and lung (Kanse et al., 1988; Richter et al., 1990; 1993; Korner et al., 2007), although expression in the human lung is restricted to small vessels (Korner et al., 2007).”
BackgroundResultInfluentialGribble, F. M., Tucker, S. J., & Ashcroft, F. M. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1145 · Cited by 341
Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes · doi:10.2337/diabetes.53.3.654 · Cited by 334 · cited 1×
“The relevance of the pharmacological effects of these metabolites is unclear, particularly given they are subject to rapid renal clearance with a half-life of less than 5 min (Ruiz-Grande et al., 1993; Meier et al., 2004).”
BackgroundVahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., et al. (2007) · Endocrinology · doi:10.1210/en.2006-0153 · Cited by 318 · cited 5×
“Vahl et al. (Vahl et al., 2007) use immunocytochemistry to demonstrate GLP-1R expression in hepatic portal vein nerve terminals; however, it must be noted that the antibody used is no longer available from AbCam, and the replacement does not recognize the GLP-1R (Panjwani et al., 2013).”
BackgroundInfluentialEvidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
Williams, D. L., Baskin, D. G., & Schwartz, M. W. (2009) · Endocrinology · doi:10.1210/en.2008-1045 · Cited by 300 · cited 2×
“In both animals and humans, GLP-1 enhances satiety (Tang-Christensen et al., 1996; Turton et al., 1996; Flint et al., 1998; Näslund et al., 1998; Williams et al., 2009; Kanoski et al., 2011; Renner et al., 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998;…”
BackgroundYamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · cited 2×
“…Journal of Pharmacology (2014) 171 1114–1128 1115 been shown to have cardioprotective and glucoregulatory actions when pharmacologically dosed (Nikolaidis et al., 2005; Meier et al., 2006; Elahi et al., 2008) and, in model animals, may exert effects independent of GLP-1R (Ban et al., 2008;…”
BackgroundEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 2×
“The effect of GLP-1 mimetics on postprandial glucose excursion is largely via slowing in gastric emptying (Meier et al., 2005; Linnebjerg et al., 2008); however, this effect is subject to tachyphylaxis (Nauck et al., 2011) and as a result, long-acting GLP-1 ana- logues are less efficacious in…”
BackgroundSUR1 Regulates PKA-independent cAMP-induced Granule Priming in Mouse Pancreatic B-cells
Eliasson, L., Ma, X., Renström, E., Barg, S., Berggren, P.-O., Galvanovskis, J., Gromada, J., Jing, X., Lundquist, I., Salehi, A., et al. (2003) · The Journal of General Physiology · doi:10.1085/jgp.20028707 · Cited by 257
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255 · cited 3×
“, 2010) and in a mouse model of pancreatic intraepithelia neoplasia, exendin treatment significantly accelerated metaplasia and lesion formation (Gier et al., 2012).”
BackgroundMoens, K., Heimberg, H., Flamez, D., Huypens, P., Quartier, E., Ling, Z., Pipeleers, D., Gremlich, S., Thorens, B., & Schuit, F. (1996) · Diabetes · doi:10.2337/diab.45.2.257 · Cited by 250
Sonoda, N., Imamura, T., Yoshizaki, T., Babendure, J. L., Lu, J.-C., & Olefsky, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710402105 · Cited by 239 · cited 1×
“…effects to directly potentiate GSIS are Gαs/cAMP dependent; however, data from the INS-1 insulinoma using supraphysiological GLP-1 stimulation in combination with β-arrestin 1 knockdown demonstrate a proportion of the cAMP/GSIS response to be β-arrestin 1 dependent (Sonoda et al., 2008).”
BackgroundDelgado-Aros, S., Kim, D.-Y., Burton, D. D., Thomforde, G. M., Stephens, D., Brinkmann, B. H., Vella, A., & Camilleri, M. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2002.282.3.g424 · Cited by 235 · cited 2×
“…al., 1998; Näslund et al., 1998; Williams et al., 2009; Kanoski et al., 2011; Renner et al., 2012) and inhibition of gastric emptying (Imeryüz et al., 1997; Näslund et al., 1998; Delgado-Aros et al., 2002; Schirra et al., 2002; 2006; Nagell et al., 2006; Hayes et al., 2008; Hellström et al., 2008).”
BackgroundPrigeon, R. L., Quddusi, S., Paty, B., & D'Alessio, D. A. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00024.2003 · Cited by 199
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · cited 2×
“In a 10 weeks trial in rats, exendin treatment resulted in significant acinar cell death and inflammation (Nachnani et al., 2010) and in a mouse model of pancreatic intraepithelia neoplasia, exendin treatment significantly accelerated metaplasia and lesion formation (Gier et al., 2012).”
BackgroundNogueiras, R., Pérez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., Haynes, W. G., Patterson, J. T., Disse, E., Pfluger, P. T., López, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5977-08.2009 · Cited by 182
Heller, R. S., Kieffer, T. J., & Habener, J. F. (1997) · Diabetes · doi:10.2337/diab.46.5.785 · Cited by 179
Hellström, P. M., Näslund, E., Edholm, T., Schmidt, P. T., Kristensen, J., Theodorsson, E., Holst, J. J., & Efendic, S. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.01079.x · Cited by 160
Wettergren, A., Wøjdemann, M., Meisner, S., Stadil, F., & Holst, J. J. (1997) · Gut · doi:10.1136/gut.40.5.597 · Cited by 153
Meier, J. J., Kemmeries, G., Holst, J. J., & Nauck, M. A. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2212 · Cited by 146
Direct effect of GLP-1 infusion on endogenous glucose production in humans
Seghieri, M., Rebelos, E., Gastaldelli, A., Astiarraga, B. D., Casolaro, A., Barsotti, E., Pocai, A., Nauck, M., Muscelli, E., & Ferrannini, E. (2013) · Diabetologia · doi:10.1007/s00125-012-2738-3 · Cited by 143 · cited 2×
“In humans, depending on experimental setting, there is a GLP-1-dependent (and insulin/glucagon independent) decrease in hepatic glucose production (Prigeon et al., 2003; Seghieri et al., 2013), an effect that can be replicated using intracerebroventricular (ICV) administration of GLP-1 in rodents (Sandoval et al.”
BackgroundBarragán, J. M., Eng, J., Rodríguez, R., & Blázquez, E. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e784 · Cited by 142 · cited 2×
“In addition, there is also evidence for GLP-1Rdependent ANS regulation of the cardiovascular system in rodents (Barragán et al., 1999; Yamamoto et al., 2002; Cabou et al., 2008; Griffioen et al., 2011), but this does not appear to be the case in humans (Bharucha et al., 2008).”
BackgroundWettergren, A., Petersen, H., ørskov, C., Christiansen, J., Sheikh, S. P., & Holst, J. J. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409092462 · Cited by 133 · cited 1×
“There is some evidence for a GLP-1dependent decrease in gastric acid secretion mediated by the ANS (Wettergren et al., 1994; 1997; 1998).”
BackgroundSchirra, J., Wank, U., Arnold, R., Göke, B., & Katschinski, M. (2002) · Gut · doi:10.1136/gut.50.3.341 · Cited by 130
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115 · cited 1×
“In addition to expression on islet beta cells, GLP-1R is present on the ductal exocrine cells [acinar (Xu et al., 2006; Gier et al., 2012)], an observation that may be important in relation to pancreatitis associated with the use of GLP-1 mimetics (see later).”
BackgroundMeier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00576.2005 · Cited by 104 · cited 1×
“…Journal of Pharmacology (2014) 171 1114–1128 1115 been shown to have cardioprotective and glucoregulatory actions when pharmacologically dosed (Nikolaidis et al., 2005; Meier et al., 2006; Elahi et al., 2008) and, in model animals, may exert effects independent of GLP-1R (Ban et al., 2008; 2010).”
BackgroundBharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · cited 2×
“In addition, there is also evidence for GLP-1Rdependent ANS regulation of the cardiovascular system in rodents (Barragán et al., 1999; Yamamoto et al., 2002; Cabou et al., 2008; Griffioen et al., 2011), but this does not appear to be the case in humans (Bharucha et al., 2008).”
Background
Cited by
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
“Indeed, different GLP-1 receptor agonists display tissue-specific pharmacology (Pabreja et al., 2014).”
BackgroundSposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
Metadata
- Authors
- Pabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-02-27
- Volume
- 171
- Issue
- 5
- Pages
- 1114-1128
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1544903325
- Cited by
- 84
- References
- 61
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.